Acceleron Reports Oral Plenary Presentation for ACE-083 in Late-Breaking Trial
December 01, 2015 at 07:03 AM EST
Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and ...